Most dark spots look the same. They don’t behave the same, and they don’t respond to the same treatments. That’s the part the product labels leave out.
When the skin experiences inflammation, a hormonal shift, or repeated sun exposure, the pigment-producing cells beneath the surface respond by making more melanin, the compound that gives skin its colour. Where that excess melanin ends up, and how long it stays, depends entirely on what triggered it in the first place.
This is not damage. It is your skin doing its job. The problem is when that response runs longer or harder than the situation called for. And the only way to address it effectively is to understand which of four very different things you are actually looking at.
The Four Types You Need to Know
Post-inflammatory hyperpigmentation follows any inflammatory event in the skin. This includes acne, eczema, cuts, burns, or an aggressive skincare product that pushed the skin too far. The excess pigment can sit close to the surface or settle deeper, depending on how severe the original inflammation was.
Fitzpatrick skin types IV through VI are at significantly higher risk of developing this type following any inflammatory trigger (Nautiyal et al., 2021). The pigment-producing cells are more reactive, the marks appear darker, and they take longer to fade. This is not a flaw in how darker skin works. It is the biology of melanin-rich skin prioritising protection over quick recovery.
On deeper skin tones, PIH can take months to years to fade without treatment, compared to weeks in lighter ones. The difference is not about healing capacity. It is about how much the skin’s protective system responds to a threat.
Melasma shows up as symmetrical patches, usually across the cheeks, forehead, bridge of the nose, or upper lip. It is driven by hormonal changes, most commonly during pregnancy or with hormonal contraceptives. UV exposure and heat make existing melasma worse, but they are not the cause.
This type is difficult to treat because the trigger is internal and ongoing. Even when treatment works, maintenance is required because the underlying hormonal sensitivity remains. Melasma is managed, not resolved.
Age spots, sun spots, whatever you prefer to call them. These develop over years of accumulated UV exposure and tend to appear on the face, hands, and shoulders, the places that have seen the most sun across a lifetime. They have defined edges and lie flat against the skin with no texture change.
They are not a sign of ageing in the way people usually mean that phrase. They are a record of sun exposure. They also do not respond to the same treatments as PIH because the cause is different, the depth is different, and the approach needs to reflect that.
Post-acne marks are a specific form of PIH that follows the inflammation of a breakout. They are frequently confused with scarring, but they are entirely different. Post-acne marks are flat discolouration. If you can feel raised or depressed areas in the skin, that is scarring and requires a different conversation entirely.
Why Your Skin Tone Changes the Whole Approach
Fitzpatrick type does not just influence how likely you are to develop hyperpigmentation. It determines which treatments are safe and which will make things worse.
The pigment-producing cells in darker skin tones are more reactive to stimulation. A treatment that safely clears sun spots on Fitzpatrick type II skin can trigger an inflammatory response that creates new, lasting pigmentation on Fitzpatrick type V skin. The laser that works for one person becomes the cause of the problem for another.
Chemical peels, laser treatments, and some topical ingredients all need adjusted concentrations and protocols depending on Fitzpatrick type. It is about understanding how the skin’s pigment response behaves differently across skin types, and choosing ingredients and protocols that work with that biology rather than against it (Alexis & Alam, 2012).
What Actually Works by Type
For PIH: vitamin C in stable forms inhibits pigment production and provides antioxidant protection. Niacinamide reduces inflammation and slows the transfer of pigment to surrounding skin cells. Tranexamic acid works well for PIH specifically by reducing inflammation and blocking one of the pathways that triggers excess pigment production. Azelaic acid addresses both the inflammatory component and pigment formation, which makes it a strong option for PIH that follows acne. For Fitzpatrick types IV through VI, gentler concentrations introduced gradually prevent the irritation that could create more pigmentation.
For melasma: tranexamic acid has shown strong results, both topically and as oral supplementation under dermatological supervision. Combined approaches using vitamin C, niacinamide, and tranexamic acid show comparable outcomes to hydroquinone with a lower risk of adverse reactions (PMC, 2025). The hormonal component means ongoing maintenance is part of the plan regardless of what is used.
For sun spots: these respond best to targeted approaches, including chemical peels with glycolic or lactic acid and retinoids that increase cell turnover and help prevent new formation. Laser treatments can be effective for Fitzpatrick types I through III when appropriate wavelengths are used. For deeper skin tones, the risk assessment matters more here than with almost any other type.
The One Thing That Applies to All Four Types
SPF every day, without exception. Sun exposure worsens every type of hyperpigmentation regardless of what else you are using. It does not just slow the healing of existing marks. It actively stimulates more pigment production, which means you can be treating and creating new discolouration at the same time if daily sun protection is not in place.
For Fitzpatrick types IV through VI, mineral sunscreens with zinc oxide or titanium dioxide avoid the white cast that makes consistent daily use harder to maintain. Consistent is the operative word. Occasional protection is not protection.
How Long It Actually Takes
PIH in superficial layers typically responds to appropriate treatment within three to six months. Deeper pigmentation can take twelve to eighteen months of consistent treatment. Melasma requires ongoing management rather than a defined end point. Sun spots respond variably depending on depth and the specific treatment used.
The factor that determines results across all four types more than any ingredient is consistency. Starting and stopping based on whether you can see immediate change is the fastest route to the cycle of disappointment. The skin works on longer timelines than most treatment marketing suggests.
Starting With the Right Diagnosis
The dark spot from last month’s breakout requires a different approach than the patches that developed during pregnancy or the marks that have appeared over years of sun exposure. The treatment may be excellent. It is simply the wrong treatment for the condition or the skin type.
Most treatment failures are not product failures. They are diagnostic ones. When you can correctly identify what you are dealing with and match it to an approach designed for your Fitzpatrick type, you stop cycling through solutions that were never built for your skin in the first place.
You finally have the correct map. That changes what you reach for next.
Sources
- Alexis, A.F., & Alam, M. (2012). Racial and ethnic differences in skin aging. Dermatologic Clinics, 30(1), 1–8.
- Alexis, A.F., et al. (2026). Noninvasive cosmetic treatments for Fitzpatrick IV–VI: a systematic review and consensus guidelines. Plastic and Reconstructive Surgery Global Open, 14(3), e4892.
- Nautiyal, A., et al. (2021). Management of hyperpigmentation: current treatments and emerging therapies. Pigment Cell & Melanoma Research, 34(6), 1000–1014.
- Passeron, T., et al. (2025). Global consensus on the management of melanin hyperpigmentation disorders: evidence-based recommendations. Journal of the European Academy of Dermatology and Venereology, 39(4), 698–712.
- Evaluation of the efficacy of a serum containing niacinamide, tranexamic acid, vitamin C, and hydroxy acid compared to 4% hydroquinone in the management of melasma. (2025). PubMed Central.